About
In this episode of LATAM MedTech Insights, we dissect the breaking news from Brazil. In the final week of March 2026, ANVISA released a surprise guidance document for Software as a Medical Device (SaMD), creating immediate and significant new hurdles for foreign manufacturers. We explore the specific changes to clinical data requirements and cybersecurity protocols that have caught the industry off guard.
This isn't just a minor update; it's a fundamental shift in how digital health products will be evaluated and approved in Latin America's largest market. We explain why your existing global data might suddenly be invalid and what this means for your product launch timelines and budgets, offering a clear-eyed look at the new landscape.
**A Case in Point:**
Imagine a promising European MedTech company, weeks from launching its revolutionary AI diagnostic tool in Brazil. Their strategy was solid, based on their successful EU MDR approval. But overnight, ANVISA's new guidance invalidates their clinical data and demands a local cybersecurity infrastructure they don't have. Their launch is frozen, and millions in projected revenue are at risk. This is the exact challenge many companies are now facing.
**Key Questions Answered in This Episode:**
* What are the most critical changes in ANVISA's new SaMD guidance you must know?
* How does the new emphasis on local Brazilian patient data impact your clinical strategy?
* Is your current cybersecurity framework compliant with the new mandatory protocols?
* Why is a CE mark or FDA clearance no longer a shortcut for entering the Brazilian market?
* What are the three most common mistakes foreign companies are making in response to this news?
* How can this regulatory hurdle be turned into a competitive advantage?
To navigate the complexities of global market access, you need a partner with deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline market entry. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market access in Brazil and beyond.
This isn't just a minor update; it's a fundamental shift in how digital health products will be evaluated and approved in Latin America's largest market. We explain why your existing global data might suddenly be invalid and what this means for your product launch timelines and budgets, offering a clear-eyed look at the new landscape.
**A Case in Point:**
Imagine a promising European MedTech company, weeks from launching its revolutionary AI diagnostic tool in Brazil. Their strategy was solid, based on their successful EU MDR approval. But overnight, ANVISA's new guidance invalidates their clinical data and demands a local cybersecurity infrastructure they don't have. Their launch is frozen, and millions in projected revenue are at risk. This is the exact challenge many companies are now facing.
**Key Questions Answered in This Episode:**
* What are the most critical changes in ANVISA's new SaMD guidance you must know?
* How does the new emphasis on local Brazilian patient data impact your clinical strategy?
* Is your current cybersecurity framework compliant with the new mandatory protocols?
* Why is a CE mark or FDA clearance no longer a shortcut for entering the Brazilian market?
* What are the three most common mistakes foreign companies are making in response to this news?
* How can this regulatory hurdle be turned into a competitive advantage?
To navigate the complexities of global market access, you need a partner with deep local expertise and a global perspective. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using advanced AI and data tools to streamline market entry. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your market access in Brazil and beyond.